Selling Your Vet Practice to a Corporate Group: The Full Financial Picture

A corporate buyer calls, offers 10× EBITDA, and the number sounds life-changing. Before you sign an LOI, you need to understand exactly what you're getting — and what you're giving up. Here's how to read a corporate offer the way a fee-only advisor would.

How corporate groups value your practice

Every corporate offer starts with normalized EBITDA — your practice's earnings before interest, taxes, depreciation, and amortization, adjusted to remove owner-specific expenses and non-recurring items.

Common add-backs (things that increase your EBITDA before pricing):

• Owner compensation above a market associate salary (~$160K for a working owner-DVM)
• Personal vehicle, phone, and non-business travel run through the practice
• One-time legal, consulting, or renovation costs
• Interest on practice loans (add-back; buyer assumes or pays off)
• Depreciation and amortization (definitional)

If your practice produces $1.8M in collections at a 28% owner net margin, your raw net is $504K. Add back $60K in personal expenses and you have ~$564K normalized EBITDA. That's the number buyers multiply — not revenue and not your take-home paycheck.

Typical deal structure (broken out)

Corporate offers almost never deliver the headline multiple as a single cash payment. A $5M offer on a $500K EBITDA practice (10× multiple) is typically structured like this:

The cash at close is real money. The equity rollover and earnout are promises — their actual value depends on future events you can't control.

Who's actually buying in 2026

The corporate vet consolidation landscape has shifted. Know who's at the table:

The real after-tax math

A $5M offer is not $5M in your pocket. Walk through the tax layers on the example above ($500K EBITDA practice, $5M offer):

Combined federal tax alone: roughly 23.8% on goodwill proceeds. In a high-tax state (CA, NY, NJ), add another 9–13%. On a $5M cash-at-close deal, your net after federal + California taxes could land around $3.2–3.5M. Still life-changing — but plan for it, don't be surprised by it.

Asset allocation battle (Section 1060): Buyers want to allocate as much as possible to non-competes and consulting agreements, which are ordinary income for you and deductible for them. You want as much as possible in goodwill (capital gains). This negotiation is worth real money — get an advisor before you sign allocation language in the LOI.

What you actually give up

Income reduction

As a practice owner netting $350K, your post-sale employment contract will typically pay you $160–200K as a producing DVM — a $150–190K/year cut in cash flow. Over a 3-year employment obligation: $450–570K in cumulative income you won't receive. This is real cost that the multiple math ignores.

Clinical autonomy

Corporate mandates vary by buyer, but commonly include: preferred lab partners (Idexx or Antech, not both), formulary restrictions on pharmaceuticals, mandatory EMR platforms, revenue-per-visit reporting, and appointment scheduling protocols. Many vets who sold rate autonomy loss as their biggest regret. Factor this into the decision — it's not just financial.

Equity rollover risk

The equity rollover (your $500K–1.25M in parent company units) has real risks:

• Illiquid until the parent exits (recap or IPO) — no timeline guaranteed
• If the PE sponsor paid a high multiple to build the platform, exit valuations may disappoint
• Several vet consolidators have had debt restructurings in 2024–2025; rollover units in distressed platforms have been written down
• You rank behind senior lenders and preferred equity in a liquidation

Model your rollover conservatively: assign it a 30–50% haircut in your personal financial plan and treat any upside as bonus.

Earnout contestability

Earnout clauses tie $250–750K to EBITDA targets in years 2–3. Buyers control the accounting. Common disputes: overhead allocation increases post-close, revenue recognition timing, and capital expenditure decisions that compress margin. Negotiate earnout protections: staffing ratios, pricing autonomy, and prohibition on new overhead allocation without consent.

Employment and non-compete terms to scrutinize

The employment agreement is as important as the purchase price. Key provisions to review:

• Compensation step-down: Does your associate pay reset at year 3? Many contracts allow the buyer to reduce compensation after the employment period ends.
• Non-compete radius and duration: Typical: 10–25 mile radius, 3–5 years. In California, Colorado, North Dakota, and Oklahoma, non-compete enforcement is severely limited or prohibited — negotiate a geographic-specific agreement if applicable.
• Good-leaver vs. bad-leaver: If you leave before the employment period ends, do you forfeit earnout? Rollover equity? Get "good-leaver" provisions for health, disability, or buyer-initiated terminations.
• Corporate sale drag-along: If the parent is acquired again (common in PE-backed platforms), what happens to your rollover equity? You need tag-along rights and anti-dilution provisions.
• Practice autonomy carve-outs: If clinical decision-making matters to you, negotiate specific language — lab vendor choice, formulary exceptions for specialty protocols, staffing approval rights.

Private SBA buyer: the alternative

A young DVM or an experienced vet acquiring through SBA financing will typically offer 5–8× EBITDA — a lower headline multiple than corporate. But the structure is different:

On a $500K EBITDA practice: a private buyer at 7× delivers $3.5M in cash with no strings. A corporate buyer at 10× delivers $3.0–4.0M cash at close plus $500K–1.25M in rollover equity that may or may not be worth face value. The risk-adjusted comparison is closer than the multiples suggest.

Decision framework

Post-sale financial planning priorities

Once a corporate sale closes, you have a liquidity event that requires immediate planning:

1. Tax withholding and estimated payments: The buyer typically withholds nothing on asset purchase proceeds. You owe estimated taxes by the quarter following closing. Work with a CPA before the wire hits.
2. Investment of proceeds: A large lump sum creates sequence-of-returns and concentration risk. A fee-only advisor can structure a systematic deployment plan — typically 12–24 months across asset classes.
3. IRMAA planning: A practice sale can spike your MAGI into the top IRMAA tier, increasing Medicare Part B premiums by $3,000–4,000/year for two years after the high-income year. Model this with your advisor.
4. Roth conversion window: If you exit practice and your income drops, the 2–3 years post-sale are often the best Roth conversion window of your career. Plan conversions before taxable account withdrawals begin.
5. Estate planning update: A liquidity event that crosses $7.5M net worth changes your estate planning needs. Update beneficiary designations, trust structures, and insurance programs immediately post-close.